Stifel initiated coverage of Lexeo Therapeutics with a Buy rating and $20 price target. For an early-stage gene therapy investment, Lexeo “checks a number of key boxes,” the analyst tells investors in a research note. The firm has bullish view on the company’s Friedreich’s Ataxia cardiomyopathy asset, LX2006, where it is optimistic that additional data in 2024 can show compelling evidence of frataxin/FXN restoration with corroboration from cardiovascular biomarkers.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LXEO: